{
    "2020-01-14": [
        [
            {
                "time": "2020-01-14",
                "original_text": "The Extreme Risks of Trading Your Own Retirement Assets",
                "features": {
                    "keywords": [
                        "Extreme Risks",
                        "Trading",
                        "Retirement Assets"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-01-14",
                "original_text": "AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.",
                "features": {
                    "keywords": [
                        "AbbVie Inc.",
                        "Moody's",
                        "ratings",
                        "review"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-14",
                "original_text": "New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks",
                "features": {
                    "keywords": [
                        "SKYRIZI",
                        "risankizumab",
                        "Cosentyx",
                        "secukinumab",
                        "Phase 3 Data",
                        "Superior"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-14",
                "original_text": "AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "MAVIRET",
                        "listed",
                        "formulary",
                        "Newfoundland",
                        "Labrador"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}